Skip to main content
Kathleen Dungan, MD, Endocrinology, Columbus, OH, Ohio State University Wexner Medical Center

KathleenMDunganMD

Endocrinology Columbus, OH

Diabetes, Lipid Metabolism

Professor of Medicine, Ohio State University

Dr. Dungan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Dungan's full profile

Already have an account?

Summary

  • Dr. Kathleen Dungan is an endocrinologist in Columbus, OH and is affiliated with multiple hospitals in the area, including Ohio State University Wexner Medical Center, James Cancer Hospital and Solove Research Institute, and Chillicothe Veterans Affairs Medical Center. She received her medical degree from Ohio State University College of Medicine and has been in practice 16 years. She specializes in diabetes and lipid metabolism.

Education & Training

  • University of North Carolina Hospitals
    University of North Carolina HospitalsFellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2006
  • University of North Carolina Hospitals
    University of North Carolina HospitalsResidency, Internal Medicine, 2001 - 2004
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 2001

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2006 - 2025
  • NC State Medical License
    NC State Medical License 2001 - 2006
  • American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • A Comparison of Continuous Intravenous Insulin and Subcutaneous Insulin among Patients with Type 2 Diabetes and Congestive Heart Failure Exacerbation 
    Columbus, OH - 6/16/2014

Press Mentions

  • Ozempic and Wegovy May Aid Anti-Cancer ‘Natural Killer’ Cells
    Ozempic and Wegovy May Aid Anti-Cancer ‘Natural Killer’ CellsMay 16th, 2023
  • Diabetes Drugs May Help Reduce Risk of Cardiovascular Events in Older Adults
    Diabetes Drugs May Help Reduce Risk of Cardiovascular Events in Older AdultsMay 8th, 2023
  • Type 2 Diabetes Drug Mounjaro Leads to 16 Percent Weight Loss in New Trial for Treatment of Overweight or Obesity
    Type 2 Diabetes Drug Mounjaro Leads to 16 Percent Weight Loss in New Trial for Treatment of Overweight or ObesityApril 28th, 2023
  • Join now to see all

Grant Support

  • Intensive Glycemic Control For Congestive Heart Failure ExacerbationNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2011
  • Glycemic Control And Variability In Congestive Heart Failure ExacerbationNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2009

Professional Memberships

Hospital Affiliations